Liver Cancer

Oligonucleotide Targets Murine Fas mRNA In Hepatocytes

Published in Hepatitis Weekly, March 26th, 2001

by N.R. Saltmarsh, staff medical writer - An oligonucleotide that targets murine Fas mRNA appears to reduce Fas expression in the liver and to protect mice from death caused by agonistic Fas antibody.

R.Z. Yu and colleagues at Isis Pharmaceuticals in California established the likely pharmacologic activity of ISIS 22023, a modified phosphorothioate antisense oligonucleotide, in a paper published in the Journal of Pharmacology and Experimental Therapeutics.

"We characterized the relationships in mice between total dose administered, dose to the target organ, and ultimately, the intracellular concentration within target cell types to the...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (2001-03-26)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry